sorafenib has been researched along with Neoplastic Processes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y; Liu, J; Pu, H; Sun, W; Xu, C | 1 |
| Gao, J; Hu, D; Hu, W; Wang, W; Yang, S; Yu, G | 1 |
2 other study(ies) available for sorafenib and Neoplastic Processes
| Article | Year |
|---|---|
Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; MicroRNAs; Neoplastic Processes; rab1 GTP-Binding Proteins; Sorafenib | 2023 |
ORM1 promotes tumor progression of kidney renal clear cell carcinoma (KIRC) through CALR-mediated apoptosis.
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Renal Cell; Caspase 3; Humans; Kidney; Kidney Neoplasms; Neoplastic Processes; Proto-Oncogene Proteins c-bcl-2; Sorafenib | 2023 |